In which therapeutic areas does Novartis Canada operate?

Novartis Canada is active mainly in cardiology, oncology, immunology/dermatology, neurosciences, ophthalmology and respiratory diseases, with a portfolio of innovative medicines and biosimilars distributed across the country.

Where are Novartis Canada's main offices located?

Novartis Pharmaceuticals Canada is headquartered in the Greater Montreal area, in Dorval (Quebec), with field teams covering every Canadian province.

Does Novartis Canada run clinical trials in Canada?

Yes. Novartis sponsors numerous Phase I to IV clinical trials in Canadian hospitals and research centers, in line with Health Canada and ICH-GCP requirements.

Novartis Canada — Novartis Canada is the Canadian affiliate of Novartis, one of the world's larges

About

Novartis is one of the world's largest pharmaceutical groups, and its Canadian affiliate has played a central role for decades in giving Canadian patients access to innovative therapies. The Canadian headquarters is located in Dorval, in Greater Montreal, with field, medical and market-access teams present in every province. The Canadian portfolio covers several high-impact therapeutic areas: cardiology (heart failure, hypercholesterolemia), precision oncology (breast and prostate cancer, hematology), immunology and dermatology (psoriasis, ankylosing spondylitis), neuroscience (multiple sclerosis), ophthalmology and respiratory disease. Novartis Canada complements this offering through Sandoz, its generics and biosimilars division. Scientifically, Novartis invests heavily in Canadian research, funds or runs numerous Phase I to IV clinical trials, and collaborates with academic hospitals, university health centers and pan-Canadian research networks. Its processes follow ICH-GCP standards and Health Canada requirements. On the patient and payer side, the company has deployed robust Patient Support Programs (PSPs), adherence programs and partnerships with provincial public drug plans and private insurers. For clinicians, hospitals, distributors and payers looking for a global pharmaceutical partner deeply rooted in Canada, capable of delivering innovation, real-world evidence and patient services together, Novartis Canada offers a rare combination of advanced pipeline, broad field presence and regulatory execution capacity.

Products

Cosentyx (sécukinumab)

Anticorps monoclonal pour psoriasis, arthrite psoriasique et spondylarthrite ankylosante.

Cosentyx (secukinumab) is a fully human monoclonal antibody that selectively targets interleukin-17A (IL-17A), a key cytokine in chronic inflammation. Marketed in Canada by Novartis, it is delivered as a subcutaneous injection following an induction-then-maintenance schedule tailored to each indication. The medicine is indicated in several IL-17A-mediated inflammatory diseases: moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis and hidradenitis suppurativa, in line with the approved labeling. Pivotal clinical studies have demonstrated a rapid and durable response, along with a well-characterized safety profile. Cosentyx is used in rheumatology, dermatology and gastroenterology, both in hospital and ambulatory settings. The product is backed by a comprehensive Patient Support Program (insurance navigation, adherence support, nurse follow-up). For clinicians and payers, benefits include proven efficacy across multiple indications, control of joint and skin symptoms, long-term safety data, Novartis support to reimbursement and access, and structured patient guidance throughout the treatment journey — making it a reliable cornerstone IL-17A therapy in Canadian practice.

Entresto (sacubitril/valsartan)

Médicament cardiovasculaire indiqué dans l'insuffisance cardiaque chronique.

Entresto (sacubitril/valsartan) is a cardiovascular medicine combining a neprilysin inhibitor (sacubitril) with an angiotensin II receptor blocker (valsartan). Marketed in Canada by Novartis, it is taken orally with gradual titration based on patient tolerability. Entresto is primarily indicated in adult patients with chronic heart failure with reduced ejection fraction (HFrEF) to reduce the risk of cardiovascular death and heart-failure hospitalization. Landmark clinical evidence (PARADIGM-HF) demonstrated its superiority over enalapril on these key endpoints. The product is used in cardiology, internal medicine and structured primary care, in close collaboration with Canadian heart-failure clinics and academic hospitals. Treatment optimization is typically supported by specialized pharmacists, nurses and cardiologists. Benefits include demonstrated reduction in cardiovascular morbidity and mortality, integration into Canadian and international heart-failure guidelines, Novartis support for therapy optimization programs, and patient guidance through a dedicated support program — all of which support long-term adherence and meaningful real-world outcomes for Canadian HFrEF patients.

Kisqali (ribociclib)

Inhibiteur de CDK4/6 pour le traitement de certains cancers du sein avancés.

Kisqali (ribociclib) is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), administered orally for the treatment of certain advanced or metastatic breast cancers. Marketed in Canada by Novartis, it is used in combination with endocrine therapy. Kisqali is indicated in women with hormone-receptor positive (HR+), HER2-negative advanced or metastatic breast cancer, in first or second line, in line with the Canadian product monograph. The MONALEESA clinical program demonstrated significant overall-survival benefit across several sub-populations, in addition to established progression-free-survival benefit. The product is used in hospital oncology, ambulatory cancer clinics and pan-Canadian cancer-care networks under close medical supervision (blood work, cardiac monitoring, adverse-event management). Benefits include demonstrated survival benefit, convenient oral administration for patients, integration into Canadian advanced breast-cancer treatment algorithms, Novartis support for reimbursement and access, and a structured patient support program that helps adherence and adverse-event management throughout the treatment journey — supporting meaningful outcomes for Canadian patients.

Pluvicto (lutétium Lu 177 vipivotide tétraxétan)

Thérapie radioligand pour le cancer de la prostate métastatique.

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a precision radioligand therapy developed by Novartis. The molecule combines a ligand that binds prostate-specific membrane antigen (PSMA) with a beta-emitting radioisotope, lutetium-177, enabling targeted irradiation of PSMA-expressing tumor cells. Pluvicto is indicated for the treatment of PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) in patients who have previously received PSMA-targeted hormonal therapy and taxane-based chemotherapy, in line with the product monograph. Its use follows a prior PSMA imaging protocol and is administered in multiple cycles in specialized centers. The product is delivered in qualified nuclear-medicine and oncology centers, in coordination with radiopharmacists, nuclear-medicine physicians and uro-oncologists. Its logistics rely on a controlled supply chain and precise scheduling driven by the radioisotope's half-life. Benefits include a precision mechanism of action, demonstrated survival data in the pivotal trial, expansion of the therapeutic arsenal in a population with limited options, and Novartis radioligand-therapy expertise to support clinical implementation across Canadian academic and regional centers — a meaningful step forward for late-line prostate-cancer care.

Services

Programmes de soutien aux patients

Programmes d'accompagnement, de remboursement et d'adhésion thérapeutique pour patients canadiens.

Novartis Canada operates comprehensive Patient Support Programs (PSPs) for patients on its specialty therapies. These programs accompany patients from prescription through therapy optimization, including access and insurance navigation. Services typically include: assessment of public and private drug coverage, support with reimbursement submissions, financial assistance where applicable, nurse phone follow-up, education on treatment administration, adverse-event management and adherence reminders. Programs comply with Canadian privacy standards (PIPEDA and equivalent provincial laws). These services are deployed across all of Novartis Canada's therapeutic areas: cardiology, oncology, immunology, neuroscience and ophthalmology. They serve patients directly as well as specialty pharmacies, hospitals and clinics managing their care. Benefits include: better treatment adherence, fewer early discontinuations, simplified insurance navigation, structured clinical support between medical visits and real-world data collection to optimize care pathways. For clinicians, these programs act as an operational extension that facilitates follow-up of patients on complex medicines across Canada — a meaningful contribution to outcomes in chronic and specialty diseases.

Essais cliniques au Canada

Conduite d'études cliniques de phases I à IV dans plusieurs centres canadiens.

Novartis Canada sponsors, funds or partners in a wide range of clinical trials across Canada, covering Phases I to IV. These studies contribute to the development of new therapies in the global Novartis portfolio and to the generation of Canadian real-world efficacy and safety data. Studies cover the company's priority therapeutic areas: oncology (solid and hematologic tumors), cardiology, immunology, neuroscience, ophthalmology and rare diseases. They are conducted in partnership with academic hospitals, university health centers, cancer centers and pan-Canadian research networks, in line with ICH-GCP and Health Canada requirements. The process includes rigorous site selection, investigator training, quality management, monitoring, pharmacovigilance and regulatory data submission. Novartis Canada provides sites with clinical, scientific and operational support infrastructure. Benefits include: early access for Canadian patients to innovative therapies, generation of Canada-specific data, strengthening of the local research ecosystem, funding of academic innovation, and active support for the development of precision-medicine programs in partner hospitals — reinforcing Canada's role in global pharmaceutical innovation.